HomeCompareSPHRF vs GBDC

SPHRF vs GBDC: Dividend Comparison 2026

SPHRF yields 606.06% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHRF wins by $280350.39M in total portfolio value
10 years
SPHRF
SPHRF
● Live price
606.06%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$280371.17M
Annual income
$211,667,981,687.60
Full SPHRF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — SPHRF vs GBDC

📍 SPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPHRFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPHRF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPHRF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHRF
Annual income on $10K today (after 15% tax)
$51,515.15/yr
After 10yr DRIP, annual income (after tax)
$179,917,784,434.46/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, SPHRF beats the other by $179,903,853,560.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHRF + GBDC for your $10,000?

SPHRF: 50%GBDC: 50%
100% GBDC50/50100% SPHRF
Portfolio after 10yr
$140195.97M
Annual income
$105,842,185,475.50/yr
Blended yield
75.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

SPHRF
No analyst data
Altman Z
11.2
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHRF buys
0
GBDC buys
0
No recent congressional trades found for SPHRF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPHRFGBDC
Forward yield606.06%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$280371.17M$20.78M
Annual income after 10y$211,667,981,687.60$16,389,263.41
Total dividends collected$274648.71M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: SPHRF vs GBDC ($10,000, DRIP)

YearSPHRF PortfolioSPHRF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$71,306$60,606.06$12,490$1,790.28+$58.8KSPHRF
2$480,183$403,885.93$16,522$3,157.73+$463.7KSPHRF
3$3,055,680$2,541,883.57$23,578$5,898.68+$3.03MSPHRF
4$18,386,820$15,117,242.14$37,115$11,886.75+$18.35MSPHRF
5$104,687,331$85,013,433.96$66,136$26,423.57+$104.62MSPHRF
6$564,382,839$452,367,394.46$137,257$66,491.44+$564.25MSPHRF
7$2,883,114,581$2,279,224,943.60$341,734$194,868.54+$2882.77MSPHRF
8$13,966,501,456$10,881,568,854.67$1,050,788$685,133.02+$13965.45MSPHRF
9$64,208,586,900$49,264,430,341.75$4,099,314$2,974,971.01+$64204.49MSPHRF
10$280,371,169,670$211,667,981,687.60$20,775,530$16,389,263.41+$280350.39MSPHRF

SPHRF vs GBDC: Complete Analysis 2026

SPHRFStock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Full SPHRF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this SPHRF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHRF vs SCHDSPHRF vs JEPISPHRF vs OSPHRF vs KOSPHRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.